Nordic Pancreatic Cancer Trial (NORPACT) – 1

Prior treatment

• Sensitivity to any of the study medications or any of the ingredients or excipients of these medications

Other illness

• Mental or organic disorders which could interfere with informed consent or treatments
• Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive cervical cancer

Lab values

• Granulocyte count < 1500 per cubic millimetre (< 1,5 x 109/L)
• Platelet count < 100 000 per cubic millimetre (< 100 x 109/L)
• Serum creatinine > 1.5 UNL (upper limit normal range)
• Albumin < 2,5 g/dl (< 25 g/L)

Age

• Female patients in child bearing age not using adequate contraception, pregnant or lactating women

Other

• Co-morbidity precluding pancreatoduodenectomy
• Percutaneous tumor biopsy
• Any reason why, in the opinion of the investigator, the patient should not participate
• Chronic neuropathy ≥ grade 2
• WHO performance score ≥ 2

• Resectable tumour of the pancreatic head radiologically strongly suspect of pancreatic adenocarcinoma
• T1-3, Nx, M0 (UICC 7th version, 2010)
• Age > 18 year and considered fit for major surgery
• Written informed consent
• Considered able to receive the study specific chemotherapy